Iovance Biotherapeutics, Inc. ( IOVA Quick Quote IOVA - Free Report) incurred loss of 51 cents per share in first-quarter 2021, wider than the Zacks Consensus Estimate of a loss of 48 cents. However, the loss narrowed from 55 cents per share reported in the year-ago quarter.
In the absence of any marketed products and revenue generating collaborations, the company did not record any revenues during the quarter.
Shares of Iovance have declined 38.3% so far this year compared with the
industry’s decrease of 6.7%. Quarter in Detail
Research & development (R&D) expenses were $55.9 million, 1.9% lower than the year-ago quarter, primarily due to lower manufacturing and clinical costs following the completion of enrollment in the pivotal cohorts for melanoma and cervical cancer studies.
General and administrative (G&A) expenses increased 41% to $19.6 million due to an increase in related personnel costs.
The company had $610.2 million in cash, cash equivalents, short-term investments and restricted cash as of Mar 31, 2021 compared with $635 million as of Dec 31, 2020.
Iovance is developing its lead pipeline candidate, lifileucel, as a monotherapy for treating metastatic melanoma and metastatic cervical cancer in separate pivotal studies.
Per a corporate update from the company in December 2020, median duration of response has not been reached in cohort 2 of the C-144-01 study after median study follow up of 28.1 months evaluating lifileucel in metastatic melanoma patients. Treatment with the candidate had achieved a 36.4% overall response rate. The company submitted additional potency assay data to the FDA to support a biologics license application (“BLA”) expected to be filed later this year. The company is also evaluating new assays for lifileucel as backup options in support of the BLA. The company continues to prepare its commercial team to support a potential launch.
Iovance is evaluating lifileucel monotherapy in patients treated with chemotherapy or anti-PD-1/PDL-1 therapies in separate cohorts of C-145-04 study. Another cohort of the study is evaluating the candidate in combination with
Merck’s ( MRK Quick Quote MRK - Free Report) Keytruda (pembrolizumab) in cervical cancer patients who are naive to anti-PD-1 therapy.
A multi-cohort phase II study — IOV-COM-202 — is evaluating lifileucel in multiple settings and indications in combination with Merck’s Keytruda or
Bristol-Myers’ ( BMY Quick Quote BMY - Free Report) Opdivo/Yervoy. The company plans to start a potential registration-directed study — IOV-LUN-202 — going forward to evaluate lifileucel in patients with recurrent or metastatic non-small cell lung cancer, without driver mutations, in patients who were previously treated with approved systemic therapy.
Another phase II study — C-145-03 — is evaluating lifileucel in head and neck squamous cell carcinoma patients.
Zacks Rank & Stocks to Consider
Iovance currently has a Zacks Rank #4 (Sell).
Atea Pharmaceuticals, Inc. ( AVIR Quick Quote AVIR - Free Report) is a better-ranked stock from the biotech sector, carrying a Zacks Rank #2 (Buy). You can see . the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here
Atea’s earnings per share estimates have increased from $3.79 to $8.34 for 2021 and from $16.76 to $17.25 for 2022 in the past 30 days.
+1,500% Growth: One of 2021’s Most Exciting Investment Opportunities
In addition to the stocks you read about above, would you like to see Zacks’ top picks to capitalize on the Internet of Things (IoT)? It is one of the fastest-growing technologies in history, with an estimated 77 billion devices to be connected by 2025. That works out to 127 new devices per second.
Zacks has released a special report to help you capitalize on the Internet of Things’s exponential growth. It reveals 4 under-the-radar stocks that could be some of the most profitable holdings in your portfolio in 2021 and beyond.
Click here to download this report FREE >>